Published by Josh White on 16th January 2024
(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.
URL: http://www.digitallook.com/dl/news/story/34028004/...